Advertisement

Management of Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Surgical Oncology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Prieto-Granada C.N.
        • Wiesner T.
        • Messina J.L.
        • Jungbluth A.A.
        • Chi P.
        • Antonescu C.R.
        Loss of H3K27me3 Expression Is a Highly Sensitive Marker for Sporadic and Radiation-induced MPNST.
        Am J Surg Pathol. 2016; 40: 479-489
        • Cheah A.L.
        • Billings S.D.
        • Goldblum J.R.
        • Carver P.
        • Tanas M.Z.
        • Rubin B.P.
        STAT6 rabbit monoclonal antibody is a robust diagnostic tool for the distinction of solitary fibrous tumour from its mimics.
        Pathology. 2014; 46: 389-395
        • Doyle L.A.
        • Vivero M.
        • Fletcher C.D.
        • Mertens F.
        • Hornick J.L.
        Nuclear expression of STAT6 distinguishes solitary fibrous tumor from histologic mimics.
        Mod Pathol. 2014; 27: 390-395
        • Dry SMaF.
        • Leiomyosarcoma S.
        WHO classification of Tumours of soft tissue and bone.
        5th edition. IARC, 2020: 195-197
        • Cancer Genome Atlas Research Network
        Electronic address edsc, Cancer Genome Atlas Research N. Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas.
        Cell. 2017; 171: 950-965 e28
        • Barretina J.
        • Taylor B.S.
        • Banerji S.
        • et al.
        Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy.
        Nat Genet. 2010; 42: 715-721
        • Chibon F.
        • Mairal A.
        • Freneaux P.
        • et al.
        The RB1 gene is the target of chromosome 13 deletions in malignant fibrous histiocytoma.
        Cancer Res. 2000; 60: 6339-6345
        • Perot G.
        • Chibon F.
        • Montero A.
        • et al.
        Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics.
        Am J Pathol. 2010; 177: 2080-2090
        • Mentzel T.
        • Calonje E.
        • Wadden C.
        • et al.
        Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the low-grade variant.
        Am J Surg Pathol. 1996; 20: 391-405
        • Lee A.Y.
        • Agaram N.P.
        • Qin L.X.
        • et al.
        Optimal Percent Myxoid Component to Predict Outcome in High-Grade Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma.
        Ann Surg Oncol. 2016; 23: 818-825
        • Fletcher C.D.
        • Gustafson P.
        • Rydholm A.
        • Willen H.
        • Akerman M.
        Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification.
        J Clin Oncol. 2001; 19: 3045-3050
        • Salo J.C.
        • Lewis J.J.
        • Woodruff J.M.
        • Leung D.H.
        • Brennan M.F.
        Malignant fibrous histiocytoma of the extremity.
        Cancer. 1999; 85: 1765-1772
        • Boughzala-Bennadji R.
        • Stoeckle E.
        • Le Pechoux C.
        • et al.
        Localized Myxofibrosarcomas: Roles of Surgical Margins and Adjuvant Radiation Therapy.
        Int J Radiat Oncol Biol Phys. 2018; 102: 399-406
        • Look Hong N.J.
        • Hornicek F.J.
        • Raskin K.A.
        • et al.
        Prognostic factors and outcomes of patients with myxofibrosarcoma.
        Ann Surg Oncol. 2013; 20: 80-86
        • Sanfilippo R.
        • Miceli R.
        • Grosso F.
        • et al.
        Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution.
        Ann Surg Oncol. 2011; 18: 720-725
        • Mutter R.W.
        • Singer S.
        • Zhang Z.
        • Brennan M.F.
        • Alektiar K.M.
        The enigma of myxofibrosarcoma of the extremity.
        Cancer. 2012; 118: 518-527
        • Haglund K.E.
        • Raut C.P.
        • Nascimento A.F.
        • Wang Q.
        • George S.
        • Baldini E.H.
        Recurrence patterns and survival for patients with intermediate- and high-grade myxofibrosarcoma.
        Int J Radiat Oncol Biol Phys. 2012; 82: 361-367
        • Lefkowitz R.A.
        • Landa J.
        • Hwang S.
        • et al.
        Myxofibrosarcoma: prevalence and diagnostic value of the "tail sign" on magnetic resonance imaging.
        Skeletal Radiol. 2013; 42: 809-818
        • Waters B.
        • Panicek D.M.
        • Lefkowitz R.A.
        • et al.
        Low-grade myxofibrosarcoma: CT and MRI patterns in recurrent disease.
        AJR Am J roentgenology. 2007; 188: W193-W198
        • Fourman M.S.
        • Ramsey D.C.
        • Kleiner J.
        • et al.
        Temporizing Wound VAC Dressing Until Final Negative Margins are Achieved Reduces Myxofibrosarcoma Local Recurrence.
        Ann Surg Oncol. 2021; https://doi.org/10.1245/s10434-021-10242-4
        • Pisters P.W.
        • Pollock R.E.
        • Lewis V.O.
        • et al.
        Long-term results of prospective trial of surgery alone with selective use of radiation for patients with T1 extremity and trunk soft tissue sarcomas.
        Ann Surg. 2007; 246: 675-681
        • Cahlon O.
        • Brennan M.F.
        • Jia X.
        • Qin L.X.
        • Singer S.
        • Alektiar K.M.
        A postoperative nomogram for local recurrence risk in extremity soft tissue sarcomas after limb-sparing surgery without adjuvant radiation.
        Ann Surg. 2012; 255: 343-347
        • Pervaiz N.
        • Colterjohn N.
        • Farrokhyar F.
        • Tozer R.
        • Figueredo A.
        • Ghert M.
        A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma.
        Cancer. 2008; 113: 573-581
        • Pasquali S.
        • Pizzamiglio S.
        • Touati N.
        • et al.
        The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial.
        Eur J Cancer. 2019; 109: 51-60
        • Callegaro D.
        • Miceli R.
        • Bonvalot S.
        • et al.
        Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis.
        Lancet Oncol. 2016; 17: 671-680
        • Gronchi A.
        • Ferrari S.
        • Quagliuolo V.
        • et al.
        Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.
        Lancet Oncol. 2017; 18: 812-822
        • Pasquali S.
        • Palmerini E.
        • Quagliuolo V.
        • et al.
        Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial.
        Cancer. 2022; 128: 85-93
        • Casali P.G.
        • Abecassis N.
        • Aro H.T.
        • et al.
        Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.
        Ann Oncol. 2018; 29: iv51-iv67
        • Judson I.
        • Verweij J.
        • Gelderblom H.
        • et al.
        Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
        Lancet Oncol. 2014; 15: 415-423
        • Maki R.G.
        • Wathen J.K.
        • Patel S.R.
        • et al.
        Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: Results of Sarcoma Alliance for Research Through Collaboration Study 002.
        J Clin Oncol. 2007; 25: 2755-2763
        • Seddon B.
        • Strauss S.J.
        • Whelan J.
        • et al.
        Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
        Lancet Oncol. 2017; 18: 1397-1410
        • van der Graaf W.T.
        • Blay J.Y.
        • Chawla S.P.
        • et al.
        Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.
        Lancet. 2012; 379: 1879-1886
        • Tawbi H.A.
        • Burgess M.
        • Bolejack V.
        • et al.
        Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.
        Lancet Oncol. 2017; 18: 1493-1501
        • Burgess M.A.
        • Bolejack V.
        • Schuetze S.
        • et al.
        Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts.
        J Clin Oncol. 2019; 37: 11015
        • D'Angelo S.P.
        • Mahoney M.R.
        • Van Tine B.A.
        • et al.
        Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
        Lancet Oncol. 2018; 19: 416-426
        • Roland C.L.
        • Keung E.Z.-Y.
        • Lazar A.J.
        • et al.
        Preliminary results of a phase II study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS).
        J Clin Oncol. 2020; 38: 11505
        • Okada T.
        • Lee A.Y.
        • Qin L.X.
        • et al.
        Integrin-alpha10 Dependency Identifies RAC and RICTOR as Therapeutic Targets in High-Grade Myxofibrosarcoma.
        Cancer Discov. 2016; 6: 1148-1165